A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate safety and assess initial efficacy of VX-509, a JAK3
inhibitor, for treatment of subjects with active RA. This study will assess the clinical
response of 4 doses of VX-509 compared to placebo when administered for 12 weeks to patients
with active RA. The study will also evaluate the safety and tolerability of VX-509 compared
to placebo when administered for 12 weeks to subjects with active RA.